New treatments and diagnostic approaches in ulcerative colitis;Nuevos tratamientos y aproximaciones diagnósticas en la colitis ulcerosa

Gastroenterologia y Hepatologia

Volumn 29, Issue SUPPL. 3, 2006, Pages 52-56

  Nos Mateu, Pilar ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b NONE   (Spain)

Author keywords

Diagnosis; Therapy; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; PREBIOTIC AGENT; SALICYLIC ACID DERIVATIVE;

CLINICAL FEATURE; DRUG EFFICACY; ENTERITIS; HUMAN; RECTUM HEMORRHAGE; REMISSION; REVIEW; ULCERATIVE COLITIS;

EID: 34547773637     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13098295     Document Type: Article

References (34)

1. Mackalski BA, Bernstein CN. New diagnostic imaging tools for inflammatory bowel disease. Gut. 2006;55:733-41.
2. Pellise M, Llach J, Bordas JM. Técnicas endoscópicas emergentes. La llegada de la histología virtual. Gastroenterol Hepatol. 2005;28:641-8.
3. Scaffidi M, Familiari L, Strangio G, Barresi G, Barresi V, Consolo P, et al. OCT patterns in ulcerative colitis. Gastroenterology. 2006;130:T1502.
4. Scaffidi M, Familiari L, Consolo P, Strangio G, Barresi G, Luigiano C, et al. OCT performance in the diagnosis of ulcerative colitis. Gastroenterology. 2006;130:T1503.
5. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-85.
6. Sandborn WJ, Kamm MA, Lichtenstein GR, Gassull M, Schreiber S, Jackowski L, et al. Combined data from two pivotal, randomized, placebo-controlled, phase III studies that SPD476, a novel mesalamine formulation given once or twice-daily, is effective for the induction remission of mild-to-moderate ulcerative colitis. Gastroenterology. 2006;130:813.
7. Gandia P, Idier I, Foldager M, Houin G. Bioequivalence of 4 g PENTASA (mesalamine) daily; dosed as 4 x 1 g Sachets or 2 x 2 x 1 g sachet. Gastroenterology. 2006;130:S1343.
8. Kornbluth A, Cuffari C, George J, Legnani P, Kissous-Hunt M, Freid-Boxt E, et al. A prospective, blinded assessment of distal colonic mucosal concentrations of 5-ASA and Nac-5ASA in UC patients treated with either Balsalazide (Colazal) or a pH-dependent mesalamine (Asacol). Gastroenterology. 2006;130:S1358.
9. Meucci G, Fasoli R, Saibeni S, Valpiani D, Gullotta R, Colombo E, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results of a prospective, multicenter study. Gastroenterology. 2006;130:S1302.
10. Lichtenstein GR, Rubin D, Regalli G, Eusebio R. Endoscopically measured mucosal healing of delayed-release oral mesalamine 4.8 g/day versus 2.4 g/day. Gastroenterology. 2006;130:T1127.
11. Borrill J, Bodger K, Bhatt A. A cost effectiveness analysis of high dose oral mesalazine for the treatment of moderately active ulcerative colitis: a decision analytic model. Gastroenterology. 2006;130:S1380.
12. Cortot A, Maetz D, Degoutte E, Dellete O, Meunier P, Tan T, et al. Similar clinical remission rates with mesalazine foam and enema in patients with active left-sided ulcerative colitis (UC): results of a multicentre, prospective, randomized, investigatorblinded, comparative study. Gastroenterology. 2006;130:814.
13. Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol. 2005;21:426-30.
14. Shanahan F, Guarner F, Von Wright A, Vilpponen-Salmela T, O'Donoghue D, Kiely B, et al. A one year, randomised, doubleblind, placebo controlled trial of a lactobacillus or a bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology. 2006;130:249.
15. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003;139:209-18.
16. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191-3.
17. Hanai H, Iida T, Takeuchi K, Yamada M, Iwaoka Y, Andoh A, et al. Curcumin, a promising drug for long-term maintenance therapy in patients with ulcerative colitis: results from a multicenter, randomized double-blind placebo-controlled clinical trial. Gastroenterology. 2006;130:572.
18. Higgins PD, Khan T, Mapili J, Zimmermann EM. Atorvastatin decreases Seo index in patients with short duration of disease in ulcerative colitis: a randomized placebo-controlled clinical trial. Gastroenterology. 2006;130:817.
19. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76.
20. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-11.
21. Jarnerot G. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology. 2006;130:286-7.
22. García-Lopez S, Gomollon-García F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol. 2005;28:607-14.
23. Nos P, Hinojosa J. Ciclosporina en el brote grave de colitis ulcerosa. Gastroenterol Hepatol. 2005;28:629-31.
24. Walsh A, Cooley R, Templeton D, Florin T, Radford-Smith G. Acute severe ulcerative colitis: A study of predictors of outcome and efficacy for cyclosporine and infliximab. Gastroenterology. 2006;130:575.
25. Wulfran C, Marc L, Philippe M, Philippe S, Isabelle N, Pauline A, et al. Predictive factors of response to cyclosporine in severe steroid-refractory ulcerative colitis. Gastroenterology. 2006; 130:927.
26. Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol. 2005;39:557-69.
27. Woo J, Sheridan J, Keller S, Hiller J, Chang YL, Lowder J, et al. Biomarkers for Visilizumab therapy of intravenous steroid refractory ulcerative colitis (IVSR-UC). Gastroenterology. 2006;130:S1322.
28. Domenech E, Hinojosa J, Esteve-Comas M, Gomollon F, Herrera JM, Bastida G, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-52.
29. Cabriada JL, Domenech E, Gomollon F, Gonzalez-Carro P, Gonzalez-Lara V, Hinojosa J, et al. Documento de consenso en el uso de la Granulocitoaferesis en pacientes con enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2006;29:85-92.
30. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-53.
31. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006;2:CD000279.
32. Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941-9.
33. Velayos F, Loftus EV Jr, Jess T, Tremaine WJ, Sandborn WJ. Colorectal cancer survival in ulcerative colitis is associated with prior use of 5-aminosalicylic acid but not surveillance colonoscopy. Gastroenterology. 2006;130:13.
34. Grimm G, Lee G, Dirisina R, Mittal N, Managlia E, Manjale J, et al. Dose-dependent inhibition of stem cell activation 5 ASA: a possible explanation for the chemo preventative effect of 5 ASA therapy in colitis-induced cancer. Gastroenterology. 2006;130:W1617.